Shire Sees Another Way To Compete With CSL Behring In HAE With New Version Of Cinryze

With Haegarda holding a convenience edge over Cinryze for HAE prophylaxis, Shire now has data showing that SHP616 also offers significant prevention of HAE attacks. How ‘616 fits into Shire’s overall HAE strategy is unclear.

chemist

Shire PLC continues to build out its hereditary angioedema franchise, announcing positive results for its Cinryze follow-on SHP616 as it also works to file for regulatory approval of its next-generation HAE prophylactic agent lanadelumab.

On Sept. 11, Shire announced that SHP616 met the primary endpoint and all other endpoints in the Phase III SAHARA...

More from Rare Diseases

More from Scrip